Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Akebia Therapeutics Ownership Summary


Akebia Therapeutics is owned by 34.84% institutional investors, 4.23% insiders, and 60.92% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.30% of AKBA shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.22% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkebia Therapeutics34.84%4.23%60.92%
SectorHealthcare Stocks 232.64%10.66%-143.30%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de19.32M7.30%$31.10M
Vanguard group16.02M6.05%$25.79M
Blackrock11.64M5.68%$11.87M
State street11.84M4.51%$32.34M
Alerce investment management5.75M2.73%$10.92M
Geode capital management6.28M2.37%$10.11M
Goldman sachs group4.71M1.78%$7.58M
Renaissance3.59M1.36%$5.78M
Qube research3.21M1.22%$8.75M
Bioimpact capital2.89M1.10%$7.89M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alerce investment management5.75M19.23%$10.92M
Bioimpact capital2.89M1.29%$7.89M
Nantahala capital management2.00M0.11%$3.22M
Entrypoint capital127.50K0.08%$205.28K
Orchard capital management53.51K0.07%$86.15K
Round rock advisors166.09K0.04%$267.40K
Sherbrooke park advisers28.39K0.04%$77.50K
Alphamark advisors38.46K0.03%$73.00K
Unified investment management18.00K0.03%$28.98K
Hennion & walsh asset management498.96K0.03%$803.33K

Top Buyers

HolderShares% AssetsChange
Blackrock11.64M0.00%9.10M
State street11.84M0.00%3.85M
Goldman sachs group4.71M0.00%2.94M
Invesco2.40M0.00%2.02M
Hrt financial lp1.62M0.01%1.59M

Top Sellers

HolderShares% AssetsChange
Morgan stanley1.23M0.00%-3.09M
Aigh capital management---2.92M
Ubs group871.53K0.00%-2.77M
Franklin resources181.62K0.00%-2.50M
Affinity asset advisors---2.45M

New Positions

HolderShares% AssetsChangeValue
Nordea investment management ab752.11K0.00%752.11K$1.21M
Hennion & walsh asset management498.96K0.03%498.96K$803.33K
Jump financial355.84K0.01%355.84K$971.45K
Voleon capital management lp211.77K0.01%211.77K$578.12K
Freestone grove partners lp202.12K0.00%202.12K$551.79K

Sold Out

HolderChange
Stephens consulting-6.00
Pnc financial services group-13.00
True wealth design-58.00
Capital performance advisors llp-68.00
Hexagon capital partners-186.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025111-39.01%92,263,820-25.41%341.57%48-56.36%35-2.78%
Sep 30, 202517212.42%122,932,54428.32%462.83%102-3.77%3454.55%
Jun 30, 20251628.72%108,281,33413.45%452.80%11119.35%23-11.54%
Mar 31, 202515019.05%95,500,61040.77%403.90%9434.29%2722.73%
Dec 31, 20241244.20%67,787,36714.05%324.04%7018.64%22-15.38%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF8.55M3.22%-46.02K
Vanguard Total Stock Mkt Idx Inv7.91M2.98%-
Vanguard US Total Market Shares ETF5.95M2.52%-
iShares Russell 2000 ETF6.27M2.36%6.27M
SPDR® S&P Biotech ETF3.09M1.17%6.91K
Vanguard Institutional Extnd Mkt Idx Tr2.90M1.09%15.52K
Fidelity Small Cap Index2.51M0.94%-2.98K
iShares Russell 2000 Value ETF1.97M0.74%1.97M
Foord Global Equity (Lux) A1.96M0.74%1.96M
Foord Global Equity Class B1.83M0.69%1.83M

Recent Insider Transactions


DateNameRoleActivityValue
Mar 04, 2026Butler John P. CEO and PresidentBuy$86.59K
Feb 02, 2026Malabre Richard C SVP, Chief Accounting OfficerSell$50.24K
Feb 02, 2026Malabre Richard C SVP, Chief Accounting OfficerSell$18.60K
Feb 02, 2026Grund Nicholas Chief Commercial OfficerSell$43.43K
Feb 02, 2026Grund Nicholas Chief Commercial OfficerSell$74.48K

Insider Transactions Trends


DateBuySell
2026 Q1115
2025 Q2-3
2025 Q1-8
2024 Q2-2
2024 Q1-10

AKBA Ownership FAQ


Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 34.84%, followed by 4.23% insiders and 60.93% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 382.13%, which Akebia Therapeutics falls below.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock funding, inc. /de (19.32M shares, 7.30%), Vanguard group (16.02M shares, 6.05%), and Blackrock (11.64M shares, 5.68%). Together, they hold 19.02% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.23% of its assets in 5.75M Akebia Therapeutics shares, valued at 10.92M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Akebia Therapeutics shares, with 3.22% of its total shares outstanding invested in 8.55M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools